Merck & Co., Inc. (MRK) Shares Bought by Strs Ohio

Strs Ohio boosted its position in Merck & Co., Inc. (NYSE:MRK) by 18.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,179,798 shares of the company’s stock after purchasing an additional 333,792 shares during the period. Merck & Co., Inc. comprises approximately 0.6% of Strs Ohio’s portfolio, making the stock its 27th biggest holding. Strs Ohio owned 0.08% of Merck & Co., Inc. worth $139,572,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the stock. Stelac Advisory Services LLC bought a new stake in Merck & Co., Inc. during the 2nd quarter valued at $104,000. Perennial Advisors LLC raised its holdings in Merck & Co., Inc. by 10.7% during the 2nd quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock valued at $104,000 after acquiring an additional 157 shares during the period. Cascade Investment Advisors Inc. raised its holdings in Merck & Co., Inc. by 15.5% during the 2nd quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after acquiring an additional 232 shares during the period. Solaris Asset Management LLC raised its holdings in Merck & Co., Inc. by 6.3% during the 2nd quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock valued at $124,000 after acquiring an additional 115 shares during the period. Finally, Harbour Capital Advisors LLC bought a new stake in Merck & Co., Inc. during the 1st quarter valued at $127,000. Institutional investors and hedge funds own 73.63% of the company’s stock.

In related news, Director Thomas H. Glocer sold 5,000 shares of the company’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total value of $281,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.25% of the stock is currently owned by insiders.

A number of brokerages have issued reports on MRK. BMO Capital Markets set a $68.00 target price on shares of Merck & Co., Inc. and gave the company a “buy” rating in a report on Wednesday, December 13th. TheStreet cut shares of Merck & Co., Inc. from a “b” rating to a “c” rating in a report on Monday, November 27th. Bank of America initiated coverage on shares of Merck & Co., Inc. in a report on Tuesday, November 28th. They issued a “buy” rating and a $64.00 price target on the stock. Deutsche Bank decreased their price target on shares of Merck & Co., Inc. from $62.00 to $59.00 and set a “hold” rating on the stock in a report on Friday, November 24th. Finally, Sanford C. Bernstein reaffirmed a “buy” rating and issued a $64.00 price target on shares of Merck & Co., Inc. in a report on Wednesday, November 15th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $66.29.

Merck & Co., Inc. (MRK) opened at $56.36 on Friday. Merck & Co., Inc. has a 1 year low of $53.63 and a 1 year high of $66.80. The stock has a market cap of $152,868.16, a price-to-earnings ratio of 33.75, a P/E/G ratio of 2.89 and a beta of 0.76. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.43 and a quick ratio of 1.16.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.08. Merck & Co., Inc. had a net margin of 11.60% and a return on equity of 27.08%. The company had revenue of $10.33 billion during the quarter, compared to analyst estimates of $10.54 billion. During the same period in the previous year, the business earned $1.07 earnings per share. The firm’s quarterly revenue was down 2.0% compared to the same quarter last year. analysts predict that Merck & Co., Inc. will post 3.95 EPS for the current fiscal year.

Merck & Co., Inc. declared that its Board of Directors has initiated a stock repurchase program on Tuesday, November 28th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

The business also recently announced a quarterly dividend, which will be paid on Monday, January 8th. Investors of record on Friday, December 15th will be given a $0.48 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.47. This represents a $1.92 annualized dividend and a yield of 3.41%. Merck & Co., Inc.’s payout ratio is 114.97%.

TRADEMARK VIOLATION WARNING: “Merck & Co., Inc. (MRK) Shares Bought by Strs Ohio” was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit